Published on October 5, 2017
Myeloma patients who have become MRD negative and are reassessing their treatment plan to prolong remission may wonder if it’s favorable to keep taking lenalidomide (Revlimid). Myeloma expert Dr. Gareth Morgan, weighs in on this decision and shares the medical practices for an optimal health outcome.
Produced by Patient Power. We thank AbbVie, Celgene, Takeda and Amgen for their support.